Clearside Biomedical, Inc. announced its exploration of strategic alternatives to advance its suprachoroidal drug delivery platform and maximize stockholder value. The company, which specializes in ...
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator ...
- Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - The publication, entitled, “Suprachoroidal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results